The 18th CROI: ARV Therapies and Therapeutic Strategies

CROI-2011_PosterProgram_Webpage_Banner.jpg 

2011_CROI_PosterPrgm_View_Button_v2.jpg 

About the Program

Program Overview

This CME activity will feature four HIV experts reviewing and discussing the most important studies presented on antiretroviral therapy at CROI. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at CROI and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This activity will enable all participating clinicians and health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.  

Back to Top  

Target Audience

This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be able to:

  • Review clinically relevant poster presentations made at the 18th CROI; 

  • Explain to colleagues the clinical trials and data presented in the most important poster presentations at the 18th CROI;

  • Discuss the scientific integrity and clinical relevance of the most important poster presentations at the 18th CROI;

  • Use the information and data presented in the most important poster presentations at the 18th CROI to improve patient care.

Release Date:  March 11, 2011

Expiration Date: March 11, 2012

Estimated time to complete each Poster/Presentation: 15-30 minutes 

Media: Internet

Back to Top

Faculty

Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts

Trevor Hawkins, MD
Associate Professor, University of New Mexico
Medical Director, Southwest CARE Center
Santa Fe, New Mexico

Paul Sax, MD 
Clinical Director, Brigham and Women's Division
of Infectious Diseases and HIV Program
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Andrew Zolopa, MD 
Associate Professor of Medicine
Division of Infectious Diseases
Stanford University School of Medicine
Palo Alto, California

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.   

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM per poster presentation. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Back to Top

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Postgraduate Institute for Medicine is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. Calvin Cohen:

  • Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; ViiV
  • Consulting Fees: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; Abbott
  • Speakers Bureau: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec

Dr. Trevor Hawkins:

  • Consulting Fees: Gilead; Merck & Co.; Tibotec
  • Speakers Bureau: Bristol-Myers Squibb; Gilead; Tibotec; Merck & Co.

Dr. Paul Sax:

  • Consulting Fees: Abbott; BMS; Gilead; GSK; Merck; Tibotec; Viiv
  • Contracted Research: Gilead; Merck; Tibotec; ViiV 

Dr. Andrew Zolopa:

  • Consulting Fees: Gilead; Tibotec; Bristol-Myers Squibb
  • Contacted Research: Bristol-Myers Squibb; Pfizer; Gilead; VIRxSyS

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM planners and managers: Jan Hixon, RN, BSN, MS, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Poster/Presentation Listing 

 

1.

2011_CROI_PosterPrgm_746.jpg Protease Inhibitor-based ART Was Associated with Pre-term
Delivery, but Not Adverse Infant Outcomes, in a Randomized
MTCT Prevention Study in Botswana

2.

2011_CROI_PosterPrgm_808.jpg No Association of Myocardial Infarction with ABC Use:
An FDA Meta-analysis
3. 2011_CROI_PosterPrgm_426.jpg Antiretroviral CPE 2010 Ranking Predicts
CSF Viral Suppression Only in Patients with
Undetectable HIV-1 RNA in Plasma
4. 2011_CROI_PosterPrgm_46.jpg Autologous CD4 T Cells (SB-728-T) in
Aviremic HIV-infected Subjects on HAART
5. 2011_CROI_PosterPrgm_150LB.jpg QDMRK, a Phase III Study of the Safety and Efficacy
of Once Daily vs Twice Daily RAL in Combination
Therapy for Treatment-naïve HIV-infected Patients
6. 2011_CROI_PosterPrgm_153LB.jpg Immunomodulatory Effects of MVC Intensification In HIV-infected Individuals with Incomplete CD4+ T Cell Recovery during Suppressive ART 
7. 2011_CROI_PosterPrgm_146LB.jpg Interim Analysis of a Phase 2a Double-blind Study of TVR in Combination with pegIFN -2a in HIV/HCV Co-infected Patients 
8. 2011_CROI_PosterPrgm_77.jpg Central Fat Accumulation in ART-naive Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: A5224s 
9. 2011_CROI_PosterPrgm_38.jpg International Randomized Trial of Immediate vs Early ART in HIV+ Patients Treated for TB: A5221 STRIDE Study 
10. 2011_CROI_PosterPrgm_95LB.jpg Adherence Indicators and PrEP Drug Levels in teh iPrEx Study 
Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.   

Back to Top

PIM_small

 Supported by an educational grant from Merck & Co., Inc.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings


Prepare to print

Share this page:

Get link code to this page     


Back to Top